CAREER PRESS CENTER DRUGS OUR ACTIVITY INNOVATION ABOUT GLENMARK HOME Glenmark Generics Ltd (GGL) ABOUT GLENMARK Overview Our vision and values Areas of activity Drug development Finished medicines Glenmark Generics Ltd (GGL) History Progress Glenmark in the World Eco concept Contacts GLENMARK GENERICS LTD (GGL) Glenmark Generics Ltd. (GGL), a subsidiary of Glenmark Pharmaceuticals Ltd., aims to become the leading integrated global generic pharmaceutical organization. The business consists of the manufacture of generics for the US and European markets, the manufacture of active pharmaceutical ingredients and the manufacture of drugs used in oncology. GGL focuses on developing, manufacturing, selling, and distributing generic drugs through wholesale distributors, retailers, pharmacy chains, and more. The main focus of GGL is on such key segments as dermatology, hormonal drugs, controlled drugs / psychotropic drugs, oncology and drugs with a sustained release formulation. GGL has a strong presence in North America, the European Union and Argentina. The company has a strong base for the development of new dosage forms and highly qualified employees who work in laboratories in India and Latin America. Glenmark owns a state-of-the-art manufacturing facility in Goa, India that is certified by the US Regulatory Authority - FDA, Canada Regulatory Authority - TPD, UK Regulatory Authority - MHRA, and many other international regulatory authorities. The American representative office of the company - Glenmark Generics, in the USA sells more than 45 drugs in various dosage forms. GGL is active in the UK generics market and has begun expanding into other EU markets. The business model for EU business is based on the sale of licenses to other companies and its own sales in these markets of competitive products. GGL also develops, manufactures and markets active pharmaceutical ingredients for other pharmaceutical companies. GGL produces about 65 different active substances on the world markets in about 65 countries, including the USA, EU countries, South America and India. So far, GGL has filed 41 more Drug Registration Dossiers with the US FDA. More details Home  •  About Glenmark  •  Innovation  •  Our Business  •  News  •  Career  •  Contact All rights reserved © Glenmark, 2010 - 2018